[ET Net News Agency, 15 October 2021] Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,
Ltd. (01349) said the company has received the acceptance notice issued by the National
Medical Products Administration of the PRC (NMPA). The investigational new drug (IND)
application for Phase II clinical trial of Aminolevulinic Acid Hydrochloride Topical
Powder on mild-tomoderate severity Actinic Keratosis (AK) of the face and scalp has been
accepted.
AK, known as photolinear keratosis, solar keratosis and senile keratosis, is a
precancerous skin lesion caused by atypical epidermal keratinocyte proliferation. It
mostly occurs in the exposed parts such as face, scalp or dorsum of the hands, and mostly
occurs in middle-aged and elderly people. (RC)